A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Phase 1 Recruiting
48 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 Recruiting
70 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
CHANCES
Phase 1 Recruiting
27 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Phase 1 Recruiting
42 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 Recruiting
135 enrolled
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
330 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1 Recruiting
200 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Phase 1 Recruiting
405 enrolled
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
VISTA
Phase 1 Recruiting
45 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Phase 1 Recruiting
150 enrolled
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Phase 1 Recruiting
18 enrolled
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
270 enrolled
IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 Recruiting
165 enrolled
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
145 enrolled
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 Recruiting
96 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase 1 Recruiting
20 enrolled
NeoTISLEGA
Phase 1 Recruiting
18 enrolled
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Phase 1 Recruiting
49 enrolled
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 Recruiting
18 enrolled
Adaptive Radiation for Abdominopelvic Metastases
Phase 1 Recruiting
30 enrolled
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Phase 1 Recruiting
108 enrolled
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
Phase 1 Recruiting
96 enrolled
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Phase 1 Recruiting
20 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
Phase 1 Recruiting
94 enrolled
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
96 enrolled
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 Recruiting
21 enrolled